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INTRODUCTION
Aminoglycosides (AG), including gentamicin, are a widely prescribed and effective class of antibiotic which have low rates of resistance. They are used in the treatment of a number of severe bacterial infections including those affecting the lungs, heart, biliary and urinary tracts [1] . However, nephrotoxicity represents a serious clinical problem in 10-15% of patients and is the dose limiting factor for their therapeutic use [2, 3] . To uncover mechanisms of AGinduced nephrotoxicity would thus be important to improve the therapeutic index and may also allow the development of novel intervention strategies. However, currently apart from once daily dosing [4] , no other clinically effective strategies exist for the prevention of AG nephrotoxicity.
Following systemic administration, AGs remain relatively unchanged and have low tissue absorption and plasma protein binding. Around 80% of the systemic dose is excreted into the urine within 24h by glomerular filtration. However, accumulation within the renal cortex, especially in the proximal tubule epithelial cells, remains high compared to other organs (5-10% dose) [5] . This is thought to be important in the pathogenesis of nephrotoxicity, and thus attention has focused on the molecular and biochemical mechanisms underpinning AG accumulation. This may be key to developing potential strategies for the intervention of toxicity.
Binding of AGs to the multi-ligand receptor, megalin, and cellular uptake by receptormediated endocytosis has been demonstrated to be the principal pathway for accumulation [6] . The abundant negative charges on the extracellular receptor domain facilitate interactions between polybasic substances such as AGs [6] . Indeed, the rank order of AG toxicity 5 (neomycin > amikacin > gentamicin = tobramycin > netilmicin) can be correlated with the ability to bind to the brush border membranes of the renal tubule [1] .
Megalin also constitutes the main endocytic pathway for the clearance of low molecular weight proteins from the glomerular filtrate, such as albumin, β2-microglobulin, transthyretin, vitamin D-binding protein and retinol binding protein [7] [8] [9] [10] . Because megalin is highly expressed in the renal cortex, it has been postulated to be a key factor in the organ specific uptake, accumulation and resulting toxicity of AGs [11] . In accordance with this, megalin knock-out mice are protected from the renal accumulation of AGs [12] . Furthermore, protein and peptide ligands which compete with AGs for binding to megalin are effective in reducing AG accumulation in cell lines expressing megalin and the appearance of urinary biomarkers of AG-induced tubular damage in vivo [13] .
Several stable proximal tubule cell lines such as those derived from the opossum kidney (OK) can be utilised to study receptor-mediated endocytosis via megalin [14, 15] . This process requires active GTP-binding proteins [16] . To function correctly, GTP-binding proteins require post-translational prenylation to anchor them and assist their translocation to cellular membranes. Isoprenoid pyrophosphates such as geranyl-geranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) are mevalonate-derived intermediates formed during the biosynthesis of cholesterol which are used for the modification of GTP-binding proteins [17] .
Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase.
They are relatively safe and are widely prescribed for the treatment of hyperlipidemia. They inhibit the rate limiting step in the sterol biochemical pathway, the conversion of HMG-CoA to mevalonate [18] . Therefore, by decreasing the intracellular sterol pool, statins can also indirectly inhibit receptor-mediated endocytosis by blocking the post-translational 6 modification of GTP-binding proteins [19] . Indeed, statins can inhibit receptor-mediated endocytosis of proteins in vitro [20] by a mechanism which correlates with the inhibition of cholesterol synthesis and an increase in the intracellular level of unprenylated GTP-binding proteins [21] . Since statins have a relatively safe clinical profile, they represent a possible strategy for the prevention of nephrotoxicity in man through the blockade of AG uptake and accumulation. Statins can also prevent other forms of renal injury through their inhibition of protein prenylation [22] . In this in vitro study, we have therefore tested the hypothesis that through the pharmacological inhibition of HMG-CoA reductase, statins can inhibit the receptor-mediated endocytosis of AGs into cultured renal proximal tubule cells and the resultant cytotoxicity. 7 
MATERIALS AND METHODS

Materials
OK cells were purchased from the European Collection of Cell Cultures (ECACC). Cell culture reagents and test reagents (gentamicin, simvastatin, pravastatin, mevalonolactone, cholesterol and [2-C 14 ] acetate were purchased from Sigma-Aldrich (Poole, UK).
Rosuvastatin was purchased from Bosche Scientific (NJ, USA). For western blotting, the NuPAGE SDS-PAGE gels were obtained from Invitrogen life sciences (Paisley, UK), the ECL-Plus and hyperfilm from Amersham biosciences (Buckinghamshire, UK) and the antibodies (total and prenylated Rap1A and anti-rabbit actin) from Santa Cruz (CA, USA).
All solvent were of high grade HPLC quality from Fischer scientific (Loughborough, UK).
Lactate dehydrogenase assay kit was purchased from Roche diagnostics (West Sussex, UK).
Cell culture treatment and cytotoxicity assessment
OK cells were used between passages 40 -55 and seeded at a density of 2x10 4 cells/cm 2 in cell culture plates containing trans-well membrane inserts to promote polarity and megalin expression. Cells were cultured until confluent prior to dosing and maintained in DMEMHam's F-12 mix containing 10% FBS, 2mmol/L L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin in a humidified atmosphere (5% CO 2 , 37⁰C). Dosing solutions were prepared in serum free media (mevalonate, gentamicin, GGPP) and as concentrated stock solutions in DMSO (pravastatin, rosuvastatin, simvastatin, GGTI-2147) or ethanol (cholesterol). Control cells were treated with 0.1% DMSO in serum free media. Cells were dosed in serum free media for up to 48h and media containing 1% serum for later time points. 
Gentamicin intracellular quantification by LC-MS/MS
Remaining cells were washed twice with ice cold PBS, lysed with RIPA buffer and kept on ice for 15min. A portion was removed for protein content determination by the methods of Bradford et al [23] and samples were centrifuged at 4⁰C for 5min at 14,000rpm. Intracellular gentamicin was detected by LC-MS/MS in multiple-reaction monitoring mode (MRM) with the main working parameters and product ion scanning based on methods described previously [24] . Analyses were performed using an Applied Biosystems/MDS Sciex Coefficient of variation calculated from 5 standard curves ran on 5 separate days was <10%
for each data point.
Cholesterol synthesis determination
Cells were incubated with test reagents for 24h and 10µCi [2-C 14 ] acetate was added for 5h.
Cells were washed twice with ice cold PBS and lysed in 0.1M NaOH. Labelled acetate M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   9 incorporation in cholesterol was determined by scintillation counting following HPLC separation as described previously [25] . Percentage (%) inhibition of cholesterol synthesis was compared to control for test reagents.
Western blotting
OK cells were washed twice with ice cold PBS, lysed in RIPA buffer and incubated on ice for 15min. Protein concentrations were determined by the Bradford assay [23] and 5µg of the total whole cell lysate was separated by SDS-PAGE. Resolved proteins were transferred to nitrocellulose membranes and probed with antibodies raised against total or unprenylated Rap1A (both 1/1000; overnight) and β-actin (1/5000; 1h). Secondary antibodies (1/10,000; 1h) were visualised by exposure to hyperfilm after incubation with ECL-Plus. Unprenylated
Rap1A levels were determined by densitometry and normalised to the level of β-actin.
Statistical analysis
Non-linear regression analysis was used to calculate inhibition constants (IC 50 ) from dose response curves recorded at 48hr post dose and statistical significance was assessed through unpaired t-test analysis, accepting P<0.05 as being significant.
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Statins inhibit GTP-binding protein prenylation in OK cells
Statins can inhibit the function of GTP-binding proteins required for receptor mediated endocytosis of low molecular weight proteins in proximal tubule cells [17, 19, 21] . We therefore explored the relationship between the inhibition of the geranyl-geranylation of a model GTP-binding protein (Rap1A) and the inhibition of gentamicin-induced cytotoxicity.
All 3 statins investigated, simvastatin, pravastatin and rosuvastatin, led to a time-and dosedependent increase in the inhibition of Rap1A prenylation as determined by western blotting using an antibody which only recognises unprenylated Rap1A [26] (IC 50 values given in table 1). Unprenylated Rap1A was absent at baseline, and in the absence of the statins, and furthermore was not induced by gentamicin treatment (Fig.1) . The total level of Rap1A remained unchanged with either gentamicin or statin treatment (Fig.1 ).
Statins inhibit gentamicin accumulation and cytotoxicity in OK cells
Gentamicin was utilised as a clinically relevant model nephrotoxic aminoglycoside.
Gentamicin intra-cellular accumulation was determined by LC-MS/MS (MRM) (Fig.2).
Gentamicin had no inhibitory effect on statin pharmacology (i.e., cholesterol synthesis inhibition) or had no inhibitory effect its self on cholesterol synthesis (Fig.3A) . Gentamicin accumulated within OK cells in a time-dependent manner which first reached significance at 2h post dose. Maximum accumulation was reached 24h post dose (Fig.3B) . The cytotoxic effect of gentamicin, analysed through LDH leakage, also showed a time dependent pattern (Fig.3C) . Cytotoxicity was first significant at time points later than 24h (0.25mg/ml). There 11 was also a direct relationship between gentamicin accumulation and cytotoxicity (R 2 =0.85) observed in OK cells (Fig.3D ). Co-administration of simvastatin blocked the intracellular accumulation of gentamicin and its cytotoxicity. Simvastatin alone did not cause a significant increase in the release of LDH (11.5±4.1%) total amount in culture media) compared to vehicle control levels (7.5±2.3%). This indicates that the inhibitory effect on gentamicin accumulation and cytotoxicity cannot be explained by statin toxicity to the OK cells. This is consistent with literature reports [21] . The effects of pravastatin and rosuvastatin were similar to those of simvastatin. Simvastatin, pravastatin and rosuvastatin were pharmacologically active in OK cells and induced a dose-and time-dependent inhibition of cholesterol synthesis from acetate ( Fig.3A and 4A ). All statins tested also induced a dose dependent inhibitory effect on the cellular unprenylation of Rap1A, accumulation of gentamicin and resulting cytotoxicity in OK cells 48hr after dosing (Fig.4B-D gentamicin. An inhibition in cholesterol synthesis of more than 60% was required to have a significant inhibitory effect on gentamicin accumulation and more than 70% to have a significant inhibitory effect on cytotoxicity in OK cells. This relationship was also mirrored 12 through the correlation between gentamicin accumulation (Fig.5C ) and cytotoxicity ( Fig.5D) and the degree to which the GTP-binding protein remained unmodified.
Addition of isoprenoid products of HMG-CoA reductase reverses the inhibitory effect of statins on gentamicin accumulation and cytotoxicity
To further define the mechanism of statin inhibition of gentamicin uptake and cytotoxicity and link it to the pharmacological action of the statin, mevalonate, GGPP and cholesterol (downstream products of HMG-CoA reductase) were co-incubated with gentamicin and simvastatin. Only mevalonate and GGPP reversed the inhibitory effect of simvastatin on gentamicin accumulation (Fig.6A) , cytotoxicity ( Fig.6B ) and Rap1A unprenylation (Fig.6C ).
The level of gentamicin accumulation, cytotoxicity and Rap1A unprenylation was comparable to that seen in cellular incubations where simvastatin was omitted. The effect of mevalonate and GGPP when co-incubated with pravastatin and rosuvastatin was the same as that seen with simvastatin.
M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Receptor-mediated endocytosis requires functional GTP-binding proteins which in turn are dependent upon C-terminal post-translational modification derived from products of the mevalonate pathway for correct function and membrane association [16, 17] . The highly potent statin, rosuvastatin, has been shown to inhibit proximal tubular uptake of low molecular weight proteins without altering renal function by a mechanism linked to the inhibition of receptor-mediated endocytosis [20, 21, 27, 28] . We hypothesised that through the pharmacological inhibition of HMG-CoA reductase, and hence mevalonate production, AG accumulation and cytotoxicity could be inhibited by licensed statins.
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A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   14 We utilised the in vitro OK cell line derived from the proximal tubule of the American opossum, to investigate the mechanism. OK cells retain megalin-mediated protein binding and uptake, dependent on GTP-protein function, comparable to in vivo situations [14, 15, 29, 30] and have previously been used to investigate AG cytotoxicity [31] and the biochemistry of statin renal transport [32] . We also cultured OK cells on trans-well membrane inserts to promote polarity and megalin expression [33] . Using this model, our data shows that gentamicin (a model nephrotoxic AG) was cytotoxic in vitro in a dose-and time-dependent manner and this was directly proportional to drug accumulation. By 24hr 100% cell death was observed with a gentamicin concentration of 1mg/ml which is comparable to literature values seen with gentamicin dosed renal tubular cells [34] . Furthermore, cytotoxicity was inhibited by statins, and this was directly due to the pharmacological action of statins and the degree of GTP-binding protein unprenylation, rather than being a function of the inhibition of AG receptor binding. [35] . Simvastatin undergoes greater than 80% hepatic extraction compared to more hydrophilic statins such as pravastatin which undergo around 45% hepatic extraction and 80% renal clearance [36] . Active tubular secretion can account for 40% of the renal clearance of pravastatin [37, 38] . Rosuvastatin undergoes 28% renal clearance, of which 90% can be accounted for by active uptake by proximal tubule cells [39] . For hydrophilic statins, such as pravastatin and rosuvastatin, OATs (organic anion transporters) localised on the basolateral membrane of proximal tubule cells have been shown to play a central role in their renal uptake. However, the expression patterns of the different sub-types of the transporters are also important. For instance, rosuvastatin is a good substrate for OAT3 and not for OAT1 [21] , whereas OK cells mainly express OAT1 [32] . It is possible that if the OK cells stably expressed the full complement of transporters observed in vivo, the inhibitory effect of the hydrophilic statins, with respect to inhibition of toxicity, would be more pronounced and the rank order of potency, with respect to inhibition of HMG-CoA reductase, would better reflect that seen clinically.
In man, animal models and the in vitro system investigated here, gentamicin nephrotoxicity is concentration-dependent being related to the degree of drug cellular uptake [1, 12] . In man and in animal models, gentamicin may take much longer to induce renal damage than that observed in our cell model. Additionally, the optimal concentration required in vivo for efficacy is around 20 times lower than the concentration used in vitro. Thus, one possible refinement of our in vitro model might be to use lower AG concentration over longer time periods [31] . However, it is important to note that (a) although the concentrations we have used are higher than those attained for efficacy, many patients achieve much higher concentrations, which is when they run into problems with nephrotoxicity; and (b) gentamicin toxicity in vivo does not solely depend on the plasma concentration, but more so A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 A c c e p t e d M a n u s c r i p t 
